文献速递药物相互作用特殊人群用药

德拉马尼及其主要代谢物DM-6705在耐药结核患者中的群体药代动力学

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.
PubMed 文献 · Clin Pharmacokinet · 2022-06-07

本研究基于DELIBERATE试验中52例耐药结核患者(26例联用贝达喹啉,20例HIV-1阳性),构建德拉马尼及其代谢物DM-6705的联合群体药代动力学模型。结果显示德拉马尼吸收平均时间1.45小时,终末半衰期15.1小时,DM-6705终末半衰期7.8天;白蛋白浓度、贝达喹啉联用及HIV感染对德拉马尼药代动力学无显著影响。

要点

  • 德拉马尼终末半衰期约15.1小时,代谢物DM-6705约7.8天
  • 贝达喹啉联用不影响德拉马尼药代动力学
  • 白蛋白浓度和HIV感染对德拉马尼代谢无显著影响

核心结论

  • 德拉马尼及其代谢物DM-6705的联合群体药代动力学模型首次建立,可用于后续暴露-效应或暴露-安全性分析。
  • 白蛋白浓度、贝达喹啉联用及HIV合并感染(联用多替拉韦)对德拉马尼和DM-6705的药代动力学无显著影响。

研究设计与样本

  • 基于DELIBERATE试验,纳入52例耐药结核患者,其中26例联用贝达喹啉,20例HIV-1阳性。
  • 采用非线性混合效应模型分析口服德拉马尼及DM-6705浓度。

主要发现

  • 德拉马尼药代动力学符合一室处置模型,含转运室吸收(平均吸收时间1.45小时[95%CI 0.501-2.20])和线性消除。
  • DM-6705药代动力学符合一室处置模型,以德拉马尼清除率为输入,线性消除。
  • 德拉马尼和DM-6705的预测终末半衰期分别为15.1小时和7.8天。
  • 白蛋白浓度对德拉马尼代谢的影响不显著。
  • 贝达喹啉联用不影响德拉马尼药代动力学;除体重异速增长外,其他人口学特征(包括HIV)均不显著。

临床怎么用

  • 临床联用贝达喹啉时无需因药代动力学相互作用调整德拉马尼剂量。
  • HIV合并感染(联用多替拉韦)或白蛋白水平异常时,德拉马尼药代动力学无显著改变,可常规使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Delamanid is a nitroimidazole, a novel class of drug for treating tuberculosis, and is primarily metabolized by albumin into the metabolite DM-6705. The aims of this analysis were to develop a population pharmacokinetic (PK) model to characterize the concentration-time course of delamanid and DM-6705 in adults with drug-resistant tuberculosis and to explore a potential drug-drug interaction with bedaquiline when coadministered. METHODS: Delamanid and DM-6705 concentrations after oral administration, from 52 participants (of whom 26 took bedaquiline concurrently and 20 were HIV-1 positive) enrolled in the DELIBERATE trial were analyzed using nonlinear mixed-effects modeling. RESULTS: Delamanid PK were described by a one-compartment disposition model with transit compartment absorption (mean absorption time of 1.45 h [95% confidence interval 0.501-2.20]) and linear elimination, while the PK of DM-6705 metabolite were described by a one-compartment disposition model with delamanid clearance as input and linear elimination. Predicted terminal half-life values for delamanid and DM-6705 were 15.1 h and 7.8 days, respectively. The impact of plasma albumin concentrations on delamanid metabolism was not significant. Bedaquiline coadministration did not affect delamanid PK. Other than allometric scaling with body weight, no patients' demographics were significant (including HIV). CONCLUSIONS: This is the first joint PK model of delamanid and its DM-6705 metabolite. As such, it can be utilized in future exposure-response or exposure-safety analyses. Importantly, albumin concentrations, bedaquiline coadministration, and HIV co-infection (dolutegravir coadministration) did not have an effect on delamanid and DM-6705 PK.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Tanneau L, Karlsson MO, Diacon AH, et al. Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. Clin Pharmacokinet. 2022. PMID: 35668346. doi:10.1007/s40262-022-01133-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。